Date Filed | Type | Description |
02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/08/2020 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 0% stake in Loxo Oncology, Inc. |
02/25/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
02/22/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
02/15/2019 |
8-K
| Quarterly results |
02/15/2019 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
02/15/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
02/15/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
02/15/2019 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
02/15/2019 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
02/15/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
02/14/2019 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 6.9% stake in Loxo Oncology, Inc. |
02/13/2019 |
SC 13G/A
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 0% stake in Loxo Oncology, Inc. |
02/12/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/11/2019 |
SC 13G/A
| VANGUARD GROUP INC reports a 9.1% stake in Loxo Oncology Inc |
02/11/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/08/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/06/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/05/2019 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
02/05/2019 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
02/01/2019 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
02/01/2019 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
02/01/2019 |
GN
| Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction |
01/17/2019 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
01/17/2019 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
01/15/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders |
01/15/2019 |
SC 13D
| LILLY ELI & CO reports a 6.6% stake in Loxo Oncology, Inc. |
01/15/2019 |
SC 13D/A
| AISLING CAPITAL III LP reports a 6.7% stake in Loxo Oncology, Inc. |
|